Meta-analysis, clinical trials, and transferability of research results into practice: The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease

Archives of Internal Medicine

Volumn 156, Issue 11, 1996, Pages 1158-1172

  Marchioli, Roberto ^a   Marfisi, Rosa Maria ^a   Carinci, Fabrizio ^a   Tognoni, Gianni ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; GEMFIBROZIL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; PROBUCOL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

ANTICHOLESTEREMIC AGENTS; CAUSE OF DEATH; CHOLESTEROL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CORONARY DISEASE; HUMANS; HYPERCHOLESTEROLEMIA; META-ANALYSIS; ODDS RATIO; PREVALENCE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS;

EID: 0029931362     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.11.1158     Document Type: Article

References (163)

1. Sackett KDL. Applying overviews and meta-analyses at the bedside. J Clin Epidemiol. 1995;48:61-66.
2. Evidence-based Medicine Working Group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA. 1992;268:2420-2425.
3. Peto R, Yusuf S, Collins R. Cholesterol-lowering trial results in their epidemiologic context. Circulation. 1985;72(suppl 3):451.
4. Yusuf S, Furberg CD. Studi su singoli fattori di rischio: controllo attraverso i cambiamenti di stile di vita. In: Olsson AG, ed. Aterosclerosi: biologia e clinica. Turin, Italy: Centro Scientifico Editore; 1989:493-496.
5. Yusuf S, Cutler J. Trials su singoli fattori: studi con farmaci. In: Olsson AG, ed. Aterosclerosi: biologia e clinica. Turin, Italy: Centra Scientifico Editore; 1989:497-502.
6. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease, II: unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA. 1988;260:2259-2263.
7. Tyroler HA. Overview of clinical trials of cholesterol lowering in relationship to epidemiologic studies. Am J Med. 1989;87(suppl 4A):14-19.
8. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323:1112-1119.
9. Rossouw JE, Lewis B, Rifkind BM. Mortality experience in cholesterol-reduction trials, N Engl J Med. 1991;324:923.
10. Holme I. An analysis of randomized trials evaluating trie effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation. 1990;82:1916-1924.
11. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301:309-314.
12. Muldoon MF, Manuck SB, Matthews KA. Mortality experience in cholesterol-reduction trials. N Engl J Med. 1991;324:922-923.
13. Silverberg JS, Henry DA. The benefits of reducing cholesterol levels: the need to distinguish primary from secondary prevention, I: a meta-analysis of cholesterol-lowering trials. Med J Aust. 1991;155:665-670.
14. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. BMJ. 1992;305:15-19.
15. Schmidt JG. Cholesterol lowering treatment and mortality. BMJ. 1992;305: 1226-1227.
16. Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. 1992;304:431-434.
17. MacMahon S. Lowering cholesterol: effects on trauma death, cancer death and total mortality. Aust N Z J Med. 1992;22:580-582.
18. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
19. Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts: treatments for myocardial infarction. JAMA. 1992;268: 240-248.
20. Cucherat M. Boissel J-P. Meta-analysis of results from clinical trials on prevention of coronary heart disease by lipid-lowering interventions. Clin Trials Meta-Anal. 1993;28:109-129.
21. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367-1373.
22. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized, controlled trials. Ann Intern Med. 1993;119:136-145.
23. Holme I. Relation of coronary heart disease incidence and total mortality to plasma cholesterol reduction in randomised trials: use of meta-analysis. Br Heart J. 1993;69(suppl 1):S42-S47.
24. Cummings P, Psaty BM. The association between cholesterol and death from injury. Ann Intern Med. 1994;120:848-855.
25. Hong MK, Mintz GS, Popma JJ, et al. Limitations of angiography for analyzing coronary atherosclerosis progression or regression. Ann Intern Med. 1994; 121:348-354.
26. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-373.
27. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308:373-379.
28. Paterson RW, Paat JJ, Steele GH, Hathaway SC, Wong JC. Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. South Med J. 1994;87:236-242.
29. Superko RH, Krauss RM. Coronary artery disease regression: convincing evidence for the benefit of aggressive lipoprotein management. Circulation. 1994; 90:1056-1069.
30. Marchioli R, Prieto JC, Tognoni G. Surrogate end-points: the case of trials on coronary atherosclerotic plaque regression. Clin Trials Meta-Anal. 1994;29: 139-176.
31. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials on cholesterol lowering and risk of stroke. Arch Intern Med. 1995;155:50-55.
32. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med. 1995;155:17-26.
33. Gould AL, Rossouw JE, Santanello NC, Heiyse JF, Furberg C. Cholesterol reduction yields clinical benefit: a new look at old data. Circulation. 1995;91: 2274-2282.
34. Collins R, Keech A, Peto R, et al. Cholesterol and total mortality: need for larger trials. BMJ. 1992;304:1689.
35. LaRosa JC. Cholesterol lowering as a treatment for established coronary heart disease. Circulation. 1992;85:1229-1235.
36. Roberts WC. Atherosclerotic risk factors: are there ten or is there only one? Am J Cardiol. 1989;64:552-554.
37. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
38. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: 1301-1307
39. Sacks FM, Pfeffer MA, Moyé L, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE). Am J Cardiol. 1991;68:1436-1446.
40. Dower M, ed. Heart Prevention Study. SCPIP. August 27, 1993:19.
41. GISSI-Prevenzione Investigators. Protocollo dello studio GISSI-Prevenzione: studio di intervento preventivo sulle componenti aterosclerotica e trombotica del rischio post-infarto. G Ital Cardiol. 1993;23:1053-1061.
42. Tognoni G, Franzosi MG, Garattini S, et al. The case of GISSI in changing the attitudes and practice of Italian cardiologists. Stat Med. 1990;9:17-27.
43. Marchioli R, Di Pasquale A, for the GISSI-Prevenzione Investigators. II quadro di riferimento biochimico, farmacologico, epidemiologico del GISSI-Prevenzione. G Ital Cardiol. 1993;23:933-964.
44. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Metaanalyses of randomized controlled trials. N Engl J Med. 1987;316:450-455.
45. Rose GA, Thomson WB, Williams RT. Corn oil in treatment of ischaemic heart disease. BMJ. 1965;1:1531-1533.
46. Low-fat diet in myocardial infarction: a controlled trial. Lancet. 1965;2:501-504.
47. Leren P. The effect of plasma cholesterol lowering diet in male survivors of myocardial infarction: a controlled clinical trial. Acta Med Scand Suppl. 1966; 466:1-92.
48. Leren P. The Oslo Diet Heart Study: eleven year report. Circulation. 1970;42: 935-942.
49. Ederer F, Leren P, Turpeinen O, Frantz ID Jr. Cancer among men on cholesterol-lowering diets: experience from five clinical trials. Lancet. 1971;2:203-206.
50. Report of a Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial intarction. Lancet. 1968;2:693-770.
51. Five year Study by a Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischaemic heart disease. BMJ. 1971;4:767-775.
52. Report by a Research Committee of the Scottish Society of Physicians. Ischemic heart disease: a secondary prevention trial using clofibrate. BMJ. 1971; 4:775-784.
53. Dewar HA, Oliver MF. Trial of clofibrate. BMJ. 1972;1:506.
54. Acheson J, Hutchinson EC. Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis. 1972;15:177-183.
55. Schoch HK. The U.S. Veterans Administration cardiology drug-lipid study: an interim report. Adv Exp Med Biol. 1968;4:405-420.
56. Detre KM, Shaw L. Long-term changes of serum cholesterol with cholesterol-altering drugs in patients with coronary heart disease: Veterans Administration drug-lipid cooperative study. Circulation. 1974;50:998-1005.
57. The Coronary Drug Project Research Group. The Coronary Drug Poject: initial findings leading to modification of its research protocol. JAMA. 1970: 214:1303-1313.
58. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
59. The Coronary Drug Project Research Group. Natural history of myocardial infarction in the Coronary Drug Project: long-term prognostic importance of serum lipid levels. Am J Cardiol. 1978;42:489-498.
60. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986: 8:1245-1255.
61. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist C, Blacket RB. Low fat low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol. 1978;109:317-330.
62. Woodhill JM, Palmer AJ, Leelarthaepin B, McGilchrist C, Blacket RB. Low fat, low cholesterol diet in secondary prevention of coronary heart disease. In. Kritchevsky D, Paoletti R, Holmes WL, eds. Drugs, Lipid Metabolism, and Atherosclerosis. New York, NY: Plenum Press; 1978.
63. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients - effect on serum cholesterol and mortality. J Chronic Dis. 1978;31:5-14.
64. McCaughan D. The long-term effects of probucol on serum lipid levels. Arch Intern Med. 1981;141:1428-1432.
65. Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study. Circulation. 1984;69:313-324.
66. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP. Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA. 1990;264:3013-3017.
67. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257: 3233-3340.
68. Carlson LA, Danielson M, Ekberg I, Klintemar B, Rosenhamer G. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis. 1977;28:81-86.
69. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
70. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on Death and Myocardial Reinfarction Trial (DART). Lancet. 1989;2: 757-761.
71. Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patient with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
72. Buchwald H, Matts JP, Fitch LL, et al. Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. J Clin Epidemiol. 1989; 42:1111-1127.
73. Buchwald H, Matts JP, Hansen BJ, Long JM, Fitch LL, and the POSCH Group. Program on Surgical Control of the Hyperlipidemias (POSCH): recruitment experience. Control Clin Trials. 1987;8:94S-104S.
74. Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268:1429-1433.
75. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? the Lifestyle Heart Trial. Lancet. 1990;336:129-133.
76. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
77. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
78. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
79. Fail PS, Sahni RC, Maniet AR, Voci G, Banka VS. The long-term clinical efficacy of lovastatin therapy following successful coronary angioplasty. Clin Res. 1992;40:400. Abstract.
80. Singh RB, Rastogi SS, Verma R, Bolaki L, Singh R. An Indian experiment with nutritional modulation in acute myocardial infarction. Am J Cardiol. 1992; 69:879-885.
81. Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ. 1992;304:1015-1019,
82. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
83. Frick MH, Heinonen OP, Huttunen JK, Koskinen P, Mänttäri M, Manninen V. Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease: an ancillary study in the Helsinki heart study frame population. Ann Med. 1993;25:41-45.
84. Blankenhorn OH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
85. Hodia HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a different effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-49.
86. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study. Lancet. 1994;344:633-638.
87. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linoleic acidrich diet in secondary prevention of coronary heart disease. Lancet. 1994; 343:1454-1459.
88. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary artherosclerosis as assessed by serial quantitative ateriography: the Canadian Coronary Atherosclerosis Intervention trial. Circulation. 1994;89:959-968.
89. Sacks FM, Pasternack RC, Gibson CM, Rosner B, Stone PH, for the Harvard Atherosclerosis Reversibility Project (HARP) Group. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentration in normocholesterolaemic patients. Lancet. 1994;344:1182-1186.
90. The Scandinavian Simvastatin Survival Study Group. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71:393-400.
91. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
92. Weintraub WS, Boccuzzi SJ, Klein L, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
93. Pitt B, Ellis SG, Mancini J, Rosman HS, McGovern ME, for the PLAC I Investigators. Design and recruitment in the United States of a multicenter quantitative angiographic trial of Pravastatin to Limit Atherosclerosis in the Coronary Arteries (PLAC I). Am J Cardiol. 1993;72:31-35.
94. Pitt B, Mancini J, Ellis SG, Rosman HS, McGovern ME, for the PLAC I Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I). J Am Coll Cardiol. 1994;A739-A742.
95. Furberg CD, Pitt B, Byington RP, Park J-S, McGovern ME, for the PLAC I and II Investigators. Reduction in coronary events during treatment with pravastatin. Am J Cardiol. 1995;76:60C-63C.
96. Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome. Control Clin Trials. 1992;13:495-506.
97. Furberg CD, Byington RP, Crouse JR, Espeland MA. Pravastatin, lipids, and major coronary events. Am J Cardiol. 1994;73:1133-1134.
98. Furberg CD, Crouse JR, Byington RP, Bond MG, Espeland MA. PLAC-2: effects of pravastatin on progression of carotid atherosclerosis and clinical events. J Am Coll Cardiol. 1993;21:71. Abstract 716-5.
99. Jukema WJ, Bruschke AVG, van Boven AJ, et al. Effect of lipid-lowering by pravastatin of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
100. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
101. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141-151.
102. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Treatment of Early Breast Cancer: Worldwide Evidence 1985-1990. New York, NY: Oxford University Press Inc; 1990;1.
103. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
104. Laupacis A, Naylor CD, Sackett DL. How should the results of clinical trials be presented to clinicians? Ann Intern Med. 1992;116(suppl 3):A12-A14.
105. Tognoni G, Bonati M. Second-generation clinical pharmacology. Lancet. 1986; 2:1028-1029.
106. Scandinavian Simvastatin Survival Study Group. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345:1274-1275.
107. Schmidt EB, Dyerberg J. Omega-3 fatty acids: current status in cardiovascular medicine. Drugs. 1994;47:405-424.
108. Steinberg D. Antioxidants in the prevention of human atherosclerosis: summary of the proceedings of a National Heart, Lung, and Blood Institute workshop: September 5-6, 1991, Bethesda, Maryland. Circulation. 1992;85: 2337-2344.
109. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms. N Engl J Med. 1994;332: 512-521.
110. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary heart disease. Circulation. 1993;87(suppl):56-66.
111. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase is sensitivity to constrictor effects of catecholamines. Circulation. 1992;85:1390-1397.
112. Quyyumi AA, Cannon RO III, Panza JA, Diodafi JG, Epstein SE. Endothelial dysfunction in patients with chest pain and normal coronary arteries. Circulation. 1992;86:1864-1871.
113. Falk E. Why do plaques rupture? Circulation. 1992;86(suppl 3):30-42.
114. Fuster V, Badimon L, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:310-318.
115. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139-2148.
116. Treasure CB, Klein L, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
117. Creager MA, Cooke JP, Mendelsohn ME, et al. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest. 1990; 86:228-234.
118. Leung W-H, Lau C-P, Wong C-K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993;341:1496-1500.
119. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
120. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet. 1992;340:1430-1432.
121. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level. J Clin Invest. 1994;93:50-55.
122. Casino PR, Crescence MK, Cannon RO III, Quyyumi AA, Panza JA. Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor Am J Cardiol. 1995;75:40-44.
123. Gordon JB, Ganz P, Nabel EG, et al. Atherosclerosis influences the vasomotor response for epicardial coronary arteries to exercise. J Clin Invest. 1989; 83:1946-1952.
124. Gage JE, Hess OM, Murakami T, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patienls with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986;73:865-876.
125. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988;77:43-53.
126. Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325:1551-1556.
127. Okumura K, Yasue H, Matsuyama K, et al. Effect of acetylcholine on the highly stenotic coronary artery: difference between the constrictor response of the infarct-related coronary artery and that of the noninfarct-related artery. J Am Coll Cardiol. 1992;19:752-758.
128. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91:29-37.
129. Vita JA, Treasure CB, Nabel EG, et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990; 81:491-497.
130. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987;80:1808-1811.
131. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 1993;92:652-662.
132. Calver A, Collier J, Vallance P, Inhibition and stimulation of nitric oxide synthesis in the human forearm bed of patients with insulin-dependent diabetes. J Clin Invest. 1992;90:2548-2554.
133. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993;71:26B-31B.
134. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75-79.
135. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
136. Plane F, Jacobs M, McManus D, Bruckdorfer KR. Probucol and other anti-oxidants prevent the inhibition of endothelium-dependent relaxation by low density lipoproteins. Atherosclerosis. 1993;103:73-79.
137. Fleischhauer FJ, Yan W-D, Fischell TA. Fish oil improves endothelium-dependent coronary vasodilation in heart transplant recipients. J Am Coll Cardiol. 1993;21:982-989.
138. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med. 1985;312:1205-1209.
139. Kromhout D. n-3 Fatty acids and coronary heart disease: epidemiology from Eskimos to western populations. J Intern Med. 1989;225(suppl 1):47-51.
140. Shekelle RB, Missell LV, Oglesby P, MacMillan-Shryock A, Stamler J. Fish consumption and mortality from coronary heart disease. N Engl J Med. 1985; 313:820.
141. Norell SE, Ahlbom A, Feychting M, Pedersen NL. Fish consumption and mortality from coronary heart disease. BMJ. 1986;293:426.
142. Dolecek TA, Grandits G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet. 1991; 66:205-216.
143. Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med. 1995;332:977-982.
144. Kalan MB. Fish and heart disease. N Engl J Med. 1995;332:1024-1025.
145. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr. 1991;53:326S-334S,
146. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.
147. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med. 1993;328:1450-1456.
148. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet. 1989;2:757-761.
149. Singh RB, Rastogi SS, Verma R, et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results ol one year follow up. BMJ. 1992;304:1015-1019.
150. de Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet. 1994; 343:1454-1459.
151. Trevisan M, Krogh V, Freudenheim J, et al. Consumption of olive oil, butter, and vegetable oils and coronary heart disease risk factors. JAMA. 1990;263: 688-692.
152. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248-254.
153. Peto R, Collins R, Gray R. Large-scale randomized evidence: large simple trials and overview of trials. J Clin Epidemiol. 1995;48:23-40.
154. Shapiro S. Point/counterpoint: meta-analysis of observational studies: metaanalysis/shmeta-analysis. Am J Epidemiol. 1994;140:771-778.
155. Petitti DB. Of babies and bathwater. Am J Epidemiol. 1994;140:779-782.
156. Greenland S. Can meta-analysis be salvaged? Am J Epidemiol. 1994;140: 783-787.
157. Shapiro S. Is there is or is there ain't no baby?: Dr Shapiro replies to Drs Petitti and Greenland. Am J Epidemiol. 1994;140:788-791.
158. Spector TD, Thompson SG. The potential and limitations of meta-analysis. J Epidemiol Community Health. 1991;45:89-92.
159. Spitzer WO. Meta-meta-analysis: unanswered questions about aggregating data. J Clin Epidemiol. 1991;44:103-107.
160. Thompson SG, Pocock SJ. Can meta-analyses be trusted? Lancet 1991;338: 1127-1130.
161. Rosendaal FR. The emergence of a new species: the professional metaanalyst. J Clin Epidemiol. 1994;47:1325-1326.
162. Cook DJ, Guyatt GH. The professional meta-analyst: an evolutionary advantage. J Clin Epidemiol. 1994;47:1327-1329.
163. Rosendaal FR. The professional meta-analyst: an evolutionary advantage (response). J Clin Epidemiol. 1994;47:1331-1332.